Ibex Medical Analytics

Deep learning on whole slide images is the product. The prostate solution analyzes scanned histopathology images from core needle biopsies stained with hematoxylin and eosin, generating heatmaps that identify tumors potentially missed on initial assessment, with case and slide level alerts. The platform extends the same approach to breast and gastric tissue. There is no manual or rules based version of finding a small cancer a pathologist already looked past.

The cleared indication is one of the most conservative and best constructed in this index: the software functions as a second read safety net running after the pathologist's initial diagnostic assessment, flagging small and rare cancers that may have been overlooked. The pathologist reads first and reaches a diagnosis independently; the AI cannot anchor that judgment because it has not spoken yet. Output is a heatmap directing attention to suspicious regions rather than a classification, which keeps interpretation with the specialist. Sequencing AI after human review rather than before is a deliberate design choice that eliminates automation bias, and few vendors make it.

Method and output are described concretely, covering input tissue preparation, heatmap generation, and the case and slide level alerting behavior. Validation was published in a peer reviewed venue, with a Lancet Digital Health study cited as supporting evidence alongside FDA submission materials. The company is candid that its precision and clinical validation studies submitted to the FDA are unpublished, which is an honest disclosure of what remains unavailable rather than an implication that everything is public. Model architecture and performance figures are not published.

Evidence combines peer reviewed publication with routine deployment scale. A Lancet Digital Health study supports the platform's diagnostic performance, and the company describes pathologists worldwide using the system as part of everyday routine for accuracy, quality control, turnaround time, and productivity, characterizing itself as the first and most widely deployed AI platform in pathology. The gap is that the specific precision and clinical validation studies underpinning the FDA clearance remain unpublished by the company's own acknowledgment, so the strongest performance evidence is not externally reviewable.

No standalone PHI framework was located, but the certification set does substantive work here: HITRUST and ISO 27001 both require documented data handling, access control, and risk management practices, and HITRUST in particular is built around healthcare information protection. That is stronger assurance than a marketing statement about security, though it is not the same as published data retention or model training terms, which were not located.

No explicit HIPAA or BAA commitment was located, though HITRUST certification is closely aligned with HIPAA security requirements and is often accepted by covered entities as evidence of an adequate control environment. A US laboratory buyer should still establish business associate terms directly with this Israel headquartered vendor.

The most complete published certification set of any vendor in this index. The company states HITRUST, Cyber Essentials Plus, ISO 27001, and ISO 13485 certifications, which is notable both for breadth and for spanning two different assurance domains: HITRUST and ISO 27001 cover information security, Cyber Essentials Plus is a UK government backed technical control scheme, and ISO 13485 is the quality management standard for medical device manufacturing. Publishing this set plainly rather than gating it behind a sales conversation sets the bar the rest of this index falls short of.

FDA 510(k) cleared as an in vitro diagnostic medical device for the prostate product, the company's first FDA clearance, covering AI generated heatmaps identifying small and rare missed prostatic cancers. International registrations extend to CE-IVD certification under the IVDR framework plus registration with the UK MHRA, Australia's TGA, and Brazil's ANVISA. Critically, the company states plainly that its prostate product is FDA cleared and its other solutions are Research Use Only in the United States, so a US buyer should understand the breast and gastric solutions are not available for clinical diagnostic use domestically. Drawing that line publicly is the practice this category requires.

No dedicated governance framework or bias evaluation was located, but ISO 13485 certification imposes a documented quality management system covering design controls and post market surveillance, which is a real governance structure even though it is not AI specific. Multi jurisdictional regulatory registration also implies validation acceptable to several independent authorities. No published subgroup or cross site performance analysis addresses scanner and staining variability.

The system operates on scanned whole slide images within pathology laboratory workflows and is described as integrated into pathologists' everyday routine across global deployments, which implies working laboratory information system and slide management integration. No named integrations, standards support, or partner platforms were enumerated in the materials reviewed.

No hosting, tenancy, or data residency terms were located. The certification set implies a documented infrastructure control environment, but where slides are processed and stored is not published and matters for laboratories operating under national data localization rules.

No published pricing or commercial model. Distribution partnerships with major diagnostics and imaging companies exist, which may mean some laboratories access the technology through an existing vendor relationship rather than direct purchase, but terms are not disclosed.

Three cancer types in routine clinical use, covering prostate, breast, and gastric, with functional coverage extending beyond detection into quality control measures and case review workflow. Geographic coverage is genuinely global, with regulatory registrations across the US, EU, UK, Australia, and Brazil. The important qualifier for US buyers is that only the prostate solution is cleared domestically; the rest is Research Use Only.